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Abstract
Two rapidly evolving fields are converging to impact breast cancer:
one has identified novel substrates of metalloproteinases that alter
immune cell function, and the other has revealed a role for
inflammation in human cancers. Evidence now shows that the
mechanisms underlying these two fields interact in the context of
breast cancer, providing new opportunities to understand this
disease and uncover novel therapeutic strategies. The metallo-
proteinase class of enzymes is well studied in mammary gland
development and physiology, but mostly in the context of extra-
cellular matrix modification. Aberrant metalloproteinase expression
has also been implicated in breast cancer progression, where
these genes act as tumor modifiers. Here, we review how the
metalloproteinase axis impacts mammary physiology and tumori-
genesis and is associated with inflammatory cell influx in human
breast cancer, and evaluate its potential as a regulator of inflam-
mation in the mammary gland.
Introduction
Breast cancer continues to be one of the leading causes of
cancer-related mortality in women in the western world. Much
like other cancers, amplifications of oncogenes or deletions
of tumor suppressor genes underlie mammary tumorigenesis.
In addition, the mammary tissue microenvironment, consisting
of structural, biochemical and cellular entities, is known to
contribute to tumor cell fate. The extracellular matrix (ECM)
acts as a junction through which these components interact
[1], with the basement membrane presenting a structural
impediment to epithelial cells during mammary remodeling
and tumorigenesis [2]. Release and activation of growth
factors and cytokines anchored to the ECM or cell surface
provide biochemical cues that exert a major influence on
tumor cell survival. Further, carcinoma-associated fibroblasts,
and inflammatory and immune cells are critical cellular entities
that affect the tumorigenic potential of the mammary stroma.
Metalloproteinases are the largest class of proteases in the
human genome [3]. Matrix metalloproteinases (MMPs), a
disintegrin and metalloproteinases (ADAMs) and tissue
inhibitors of metalloproteinases (TIMPs) together comprise an
important proteolytic axis. There are 23 MMP [4], 13 cata-
lytically active ADAM [5,6], 19 ADAM with a thrombospondin
domain (ADAMTS) [6], and 4 TIMP [7] proteins in humans.
As a whole, this axis has long been recognized for its
regulatory role in matrix turnover and growth factor bio-
availability. Using various model systems, studies have
explored the effects of these individual proteases and
inhibitors on cancer hallmarks such as cell proliferation,
apoptosis, invasion and metastasis (reviewed in [7,8]). A
novel dimension to the metalloproteinase axis is its ability to
regulate many critical aspects of immunity and inflammation.
This is achieved through clipping, shedding, and regulated
intramembrane processing (RIPping) of key substrates in the
tissue microenvironment, as described in our recent review
[9]. These processes now add another mechanistic link
between metalloproteinases and the inflammatory contribu-
tion to tumorigenesis.
In breast cancer, epidemiological evidence suggests that
inflammation is associated with poor prognosis. Here we ask
whether the emerging role of metalloproteinases in inflam-
mation extends to breast cancer. We review literature on
mammary gland physiology, murine mammary tumor models
and clinical breast cancer studies, in each case summarizing
Review
Inflammation and breast cancer
Metalloproteinases as common effectors of inflammation and
extracellular matrix breakdown in breast cancer
Carlo V Hojilla1, Geoffrey A Wood2 and Rama Khokha1
1Department of Medical Biophysics, Ontario Cancer Institute, Toronto, M5G 2M9 Canada
2Department of Pathobiology, University of Guelph, Guelph, N1G 2W1 Canada
Corresponding author: Rama Khokha, rkhokha@uhnres.utoronto.ca
Published: 31 March 2008 Breast Cancer Research 2008, 10:205 (doi:10.1186/bcr1980)
This article is online at http://breast-cancer-research.com/content/10/2/205
© 2008 BioMed Central Ltd
ADAM = a disintegrin and a metalloproteinase; ADAMTS = ADAM with a thrombospondin domain; CSF = colony stimulating factor; ECM = extra-
cellular matrix; EGFR = epidermal growth factor receptor; GM-CSF = granulocyte macrophage colony stimulating factor; HER = human epidermal
growth factor receptor; MMP = matrix metalloproteinase; MMTV = mouse mammary tumor virus; RECK = reversion-inducing cysteine-rich protein
with Kazal motifs; RIPping = regulated intramembrane processing; TIMP = tissue inhibitor of metalloproteinase; TNF = tumor necrosis factor.Page 2 of 9
(page number not for citation purposes)
Breast Cancer Research    Vol 10 No 2 Hojilla et al.
what is known regarding the metalloproteinase axis as well as
seeking evidence for its role as a mediator of inflammation.
We also comment on the emerging contribution of the
metalloproteinase axis to immune cell function, its correlation
with lymphocytic infiltrate positivity in breast cancer and its
potential to bridge inflammation and ECM breakdown in this
disease.
Determinants of mammary gland
morphogenesis and involution
Metalloproteinase-mediated ECM remodeling
Altered metalloproteinase activity has a direct impact on
mammary gland physiology as controlled remodeling of
mammary gland ECM through pericellular proteolysis is
important for mammary morphogenesis, cyclical changes
during the estrous cycle, and the differentiation necessary for
lactation. Although ECM breakdown is required by epithelial
cells, stromal cells, including fibroblasts, as well as inflam-
matory and immune cells are major producers of metallo-
proteinases [2]. In addition, ADAM proteases operate as
sheddases for cell surface substrates and participate in
stromal-epithelial cross-talk through paracrine delivery of
signals [10]. Finally, TIMPs, as inhibitors of metallo-
proteinases, are critical regulators of matrix turnover in the
mammary gland. The spatial localization of proteins of the
metalloproteinase axis may be particularly important for the
orchestration of these events.
During mammary morphogenesis in the mouse, MMP3
localizes to elongating ducts [11] and its overexpression
results in supernumerary ductal branching [12]. MMP2 and
MMP14 deficient mice display diminished ductal elongation,
whereas MMP9 deficiency has no effect [13]. ADAM17 plays
a role in paracrine communication involving epithelial-specific
amphiregulin and stromally restricted epidermal growth factor
receptor (EGFR) [14]. Specifically, Amphiregulin-/- mammary
glands have impaired ductal outgrowth [15], while Adam17-/-
mammary glands have severe growth and branching
retardation that phenocopies EGFR-deficient mammary glands
[14]. Manipulation of TIMP levels also leads to alterations in
mammary morphogenesis. Reduction of TIMP1 expression
through antisense RNA production leads to more extensive
branching, increased ductal elongation, and increased
proliferative index. Conversely, TIMP1 upregulation leads to
inhibition of ductal elongation without affecting bifurcation or
lateral budding [16]. TIMP3 deficient mice also show
accelerated ductal elongation but normal branching patterns
[17]. Orthotopically implanted TIMP-containing pellets result
in inhibition by TIMP4, but promotion by TIMP2 of ductal
outgrowth [17]. Thus, individual members of the metallo-
proteinase axis are not necessary for gland development per
se, but are required for refining the ductal and branching
patterns within the mammary gland. This is emphasized by
the fact that most phenotypes in genetic models of MMPs
and TIMPs are transient; the glands become lactationally
competent when brought to parturition.
Reversion of a lactating gland to a virgin-like state during
involution requires an extensive remodeling of the ECM along
with epithelial cell death. The first and second phases of
involution have been designated protease-independent and
protease-dependent stages, respectively, based on the
expression of MMPs and TIMPs [18]. Mammary gland
involution is accelerated upon mammary-specific over-
expression of an autoactivating form of MMP3, due to
unscheduled apoptosis early in pregnancy [19]. In contrast,
excess TIMP1 delivered through an implanted pellet delays
gland regression [20]. TIMP3 is produced by epithelia and
stroma and its loss leads to accelerated involution that
cannot be rescued by re-initiation of suckling [21]. The sub-
strates of MMPs that have been identified during involution
include components of the ECM, as well as proteins involved
in cell-cell, and cell-ECM adhesion. MMP3 cleaves the ECM
protein entactin, which interacts with other ECM proteins and
integrins [19]. TIMP3 deficiency leads to fibronectin
fragmentation [21] and liberates the DIII fragment of laminin-5
during involution, which activates EGFR [22]. Metallo-
proteinases fragment E-cadherin, releasing a degradation
product that further destabilizes E-cadherin function,
compromising epithelial integrity during involution [23,24].
MMPs and TIMPs are also implicated in regulating adipo-
genesis during the third phase of mammary gland involution.
While genetic deletion of MMP3 in the gland does not affect
epithelial apoptosis, immature adipocytes have increased
differentiation, displaying accelerated adipogenesis; an effect
phenocopied by TIMP1 overexpression [25]. These studies
highlight the importance of tissue interactions during
involution, with the mammary stroma actively contributing
towards epithelial cell death.
The immune system
A review by Vorbach and colleagues [26] presented a
concept that the mammary gland may have evolved from the
innate immune system. This hypothesis suggests that the
gland’s initial function was the provision of innate immunity,
and its nutritional role evolved later. Indeed, failure of passive
transfer of immunity from mammary gland secretions to
mammalian newborns can contribute to neonatal mortality.
Various studies show that immune cells are present in the
mammary stroma and are implicated in gland development. In
humans, extramedullary hematopoietic cells have been found
in the stroma of the infant breast anlage [27]. Leukocytic
infiltrates have been documented throughout pubertal and
adult breast development [27]. Colony stimulating factor
(CSF)-1 mutant mice (Csf1op/op) that lack macrophages, or
mice deficient in eotaxin, a chemokine that recruits eosino-
phils, have impaired formation of terminal end buds, ductal
invasion, and ductal branching [28]. Whole body irradiation
with a sublethal dose that depletes the bone marrow leads to
impaired epithelial ductal elongation, suggesting a general
role for immune cell involvement in murine gland development
[28]. Expression of inflammatory mediators and acute phase
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macrophages and eosinophils in involuting glands all point to
a role for inflammation [29,30]. The local tissue deconstruc-
tion during this process may be facilitated by the activation of
innate immune components, with macrophages likely
performing a corpse-clearing function [31]. At present, very
little is known about the presence or role of components of
the adaptive immune system in mammary gland physiology.
Further, the role of the metalloproteinase axis in mediating
inflammation and immunity during morphogenesis and
involution currently remains unexplored.
Determinants of murine mammary
tumorigenesis
Metalloproteinases as tumor modifiers
Genetic mouse models are powerful tools for understanding
the role of specific genes in breast cancer development.
MMP3 overexpression driven by the whey acidic protein
promoter or MMP7 overexpression under the mouse mammary
tumor virus (MMTV) promoter both lead to mammary tumor
formation at low frequency [32,33], while MMP7 deficiency
results in 60% reduction of early mammary lesions in a
chemical carcinogenesis model [34]. MMTV-ras mice lacking
MMP11 have significantly increased survival and a smaller
tumor burden compared to wild type but develop significantly
more metastatic lesions [35]. Overexpression of the
membrane-anchored MMP14 in the mammary epithelium
leads to increased lymphocytic infiltrates, periductal fibrosis,
ductal hyperplasia with dilated ducts, dysplasia, and
adenocarcinoma in multiparous transgenic mice [36]. The
effect of TIMP1 on mammary tumorigeneis has been
assessed in transgenic mice that either secreted TIMP1
systemically using an albumin promoter, or expressed it in a
mammary-specific manner using the MMTV promoter [37].
When subjected to the DMBA model of mammary
carcinogenesis or crossed with MMTV-PyMT mice, systemic
TIMP1 elevation reduced tumor burden by 70% and 44%,
respectively. Metastasis was also inhibited. Interestingly,
mammary-specific TIMP1 overexpression was ineffective
against mammary tumorigenesis in both models. On the other
hand, a recent report showed inhibition of MCF10A (non-
transformed, immortalized mammary epithelial cells) apop-
tosis by recombinant TIMP1 in a metalloproteinase inhibitor-
independent capacity [38]. A recent study has revealed that
TIMP2 overexpression in the mammary gland increases
MMTV-Wnt1-induced mammary tumor latency, with tumors
showing lower bromodeoxyuridine and CD31 positivity, and
higher TUNEL (terminal deoxynucleotidyl transferase-
mediated dUTP nick end labeling) positivity compared to
wild-type Wnt1 tumors [39]. Thus far, genetic studies that
address the role of TIMP3 or TIMP4 in mammary tumori-
genesis are lacking, although several in vitro and clinical
reports suggest that these remaining TIMPs may also be
important. For instance, overexpression of engineered mutant
TIMP3 protein that mimics the Sorsby’s Fundus Dystrophy
mutation promotes apoptosis in MCF-7 cells [40], and
metastasis of TIMP3 overexpressing MDA-MB-435 breast
cancer cells is significantly reduced [41]. Notably, Timp3 is
found silenced by promoter methylation in a panel of human
cancer cell lines derived from primary breast cancers and
metastases to brain [42-45]. TIMP4 was originally identified
in human breast cancer [46] and its overexpression in human
breast cancer cells diminishes growth and metastasis in
athymic mice [47]. Individual members of the metallo-
proteinase axis investigated to date are able to function as
tumor modifiers in a variety of breast cancer models, with
increased MMP or decreased TIMP activity generally
associated with tumor promotion. Future investigations
exploring non-proteolytic functions of members of this axis, as
well as characterizing newer members such as ADAMs and
ADAMTSs, will better define their specific contribution to
mammary tumorigenesis.
Inflammatory mediators as tumor modifiers
Classically, inflammation is associated with immune surveil-
lance against neoplasms [48], and tumors are known to
develop strategies to circumvent immune recognition and
clearance. Although mouse models provide an opportunity to
directly test the specific role of individual inflammatory and
immune cell types and effector molecules such as cytokines
in mammary tumourigenesis, there has been very little work
addressing this important issue. A few studies using mice
point to a protective role of immune cells in tumorigenesis:
concurrent lack of the immune mediators granulocyte
macrophage CSF (GM-CSF)1 and interferon-γ lead to spon-
taneous tumor formation in mice, including mammary
adenocarcinoma [49]; and the loss of neutrophil collagenase,
MMP8, leads to increased susceptibility to skin cancer due to
ineffectual neutrophil infiltration, indicating the importance of
a timely inflammatory response in protecting against skin
carcinogenesis [50]. In contrast, other studies have pointed
to a pro-tumorigenic role for inflammatory cells, specifically
tumor-associated macrophages [51] and B cells [52]. These
cells are postulated to foster tumor growth and metastasis
through release of cytokines and matrix remodeling enzymes.
Genetic crosses of macrophage-deficient, osteopetrotic mice
that are mutant for the macrophage growth factor CSF1
(Csf1op/op) with MMTV-PyMT mice show reduced
progression to malignancy and metastatic disease [53]. Mice
that are deficient in cyclooxygenase-2 have decreased levels
of prostaglandin E2 and decreased tumor multiplicity [54]
when crossed into the breast cancer model expressing the
activated form of Neu/human epidermal growth factor
receptor (HER)2 (MMTV-NeuNDL - neu deletion mutant).
A system to study the importance of a wide variety of immune
and inflammatory cells as well as cytokines on mammary
tumorigenesis exists in the MMTV-PyMT model. Beyond
macrophages, we have observed other inflammatory and
immune cell types, namely CD3+ T lymphocytes, B cells,
mast cells, and neutrophils in and around the mammary
tumors arising in MMTV-PyMT mice (Figure 1). The presence
of these cells provides an opportunity to study the effect of
Available online http://breast-cancer-research.com/content/10/2/205specific cell types and effector molecules in mammary tumor
progression by crossing this model to mice with the desired
gene deficiencies. Although the MMTV-PyMT model has rela-
tively high tumor multiplicity and short latency, histological
analyses reveal that this model shares molecular and morpho-
logical characteristics with human breast cancer [55] as well
as the immune and inflammatory cell populations shown in
Figure 1. Additionally, the role of metalloproteinase axis
members that are linked to regulation of inflammation can be
functionally assessed using this model in combination with
mice deficient in the protease or inhibitor of interest.
Human breast cancer studies
The metalloproteinase axis in breast cancer progression
Many studies have attempted to correlate MMP, ADAM and
TIMP expression profiles with breast cancer progression and
common trends have emerged (reviewed in [56,57]). The
levels of MMP expression usually correlate with aggressive
breast tumors, those of individual TIMPs suggest a more
complex association with breast cancer, while data on ADAM
and ADAMTS expression in breast cancer are relatively
recent [7,57,58]. High levels of MMP9, which degrades type
IV collagen in basement membrane, is associated with poor
prognosis in breast cancer independent of the cell type
expressing this protease [59,60]. Patients with atypical ductal
hyperplasia are at increased risk of developing invasive breast
cancer. MMP1 protein was detectable in a subgroup of
patients with atypical ductal hyperplasia that had a history of
cancer [61] and this protease was found in ductal lavage,
leading to the suggestion that MMP1 may identify atypical
ductal hyperplasia patients that are at risk for developing
breast cancer. Studies on TIMP1 expression in breast cancer
show both a role for and against it as a positive prognostic
factor [58], owing to its diverse effects on cellular prolifera-
tion, angiogenesis, and apoptosis, as detailed in a recent
review by Cruz-Munoz and Khokha [7]. Lipton and colleagues
[62] measured plasma TIMP1 levels via ELISA (enzyme-linked
immunosorbent assay) and correlated its elevation with
higher serum HER2 levels, increased metastasis, and reduced
survival in breast cancer patients. Real time-PCR analysis of
breast cancer tissue correlated TIMP3 overexpression with
success of adjuvant endocrine therapy [63,64]. Similarly,
TIMP3 mRNA levels in breast tumors significantly associated
with good prognosis and longer disease-free survival [65]. In
contrast, TIMP3 levels were found to be higher in
mammographically dense breasts, which are considered to
be at a higher risk for developing breast cancer [66]. In
another study, higher mRNA expression of the membrane-
anchored MMP inhibitor RECK (reversion-inducing cysteine-
rich protein with Kazal motifs) in breast tumors was found to
be an independent prognostic indicator associated with a
longer relapse-free survival time [67].
In a tissue microarray study of primary invasive ductal
carcinoma, high individual expression of MMP9, MMP11,
TIMP1, and TIMP2 was significantly associated with
increased incidence of metastasis at five years post-surgical
resection [68]. When the authors accounted for cell type-
specific expression (tumor cells, fibroblasts, inflammatory
mononuclear cells), additional specific members (MMP1,
MMP7, MMP13, MMP14, TIMP3) had significant associa-
tions with developing metastastic disease [68]. In a follow-up
study [69], the most powerful indicator of distant relapse-free
survival in breast cancer patients was a set of MMPs and
TIMPs whose expression was specific to tumor-associated
mononuclear inflammatory cells. Similarly, separating breast
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Figure 1
Immune cells in mammary tumours arising from PyMT expression. (a-e) Immunostaining for various bone marrow derived cells, and (f) toludine blue
staining for mast cells in MMTV-PyMT mammary tumors. Macrophages are commonly present within and around tumors (a,b). Arrows indicate
macrophages (b), T-cells (c), B-cells (d), neutrophils (e), and mast cells (f). T- and B-cells are often present as groups of mixed lymphocytes at the
borders of lesions, and are more frequent than neutrophils unless necrosis is present. Mast cells are the most rare, and are usually solitary or in
groups of two to three cells.tumor tissue into different cellular components revealed that
TIMP3 was not present in ductal carcinoma in situ or normal
epithelium, but was significantly overexpressed in myofibro-
blasts and myoepithelial cells surrounding ductal carcinoma
in situ [70]. Thus, such profiles were less informative when
bulk tumor, fibroblasts, or tumor cells were analyzed,
suggesting that monitoring inflammatory cell-specific expres-
sion may provide clinically important insights. Future studies
must consider the cell- and stage-specific patterns of these
proteins to resolve present evidence that is limited and at
times contradictory with respect to the association of TIMP
expression with breast cancer.
ADAM and ADAMTS metalloproteinases are becoming
recognized as important factors in breast cancer. ADAM9,
ADAM12, ADAM15, ADAM17, ADAM23, ADAM28, and
ADAMTS1 have all been found in breast cancer [5,6]. Levels
of ADAM9 correlate positively with HER2 levels [6] and with
positive response to Tamoxifen [5]. A possible diagnostic role
for the soluble form of ADAM12 has been proposed since
urine levels of this metalloproteinase positively correlate with
breast cancer progression [5]. ADAM17 is overexpressed in
breast tumors and its inhibition leads to decreased cell
proliferation in vitro or tumor growth in xenograft models [5].
The critical role of ADAM17 in mediating tumor necrosis
factor (TNF)-initiated inflammation [71] and/or its role in
transactivating EGFR through the cleavage of EGF ligands
such as transforming growth factor-α may underlie these
effects [10]. Although the biology of ADAMs is less
understood than that of MMPs, their ability to shed cell
surface molecules qualifies them and their substrates as
candidates for breast cancer progression biomarkers.
The metalloproteinase axis potentially links
inflammation and breast cancer
The importance of cytokine signaling as a link between
inflammation and cancer has been highlighted [72], and the
bioavailability of many of these critical molecules is regulated
by the metalloproteinase axis. Figure 2 illustrates the metallo-
proteinases and the potential substrates linked to specific
aspects of an inflammatory or immune response, such as the
generation of chemokine gradients, immune cell influx,
lymphocyte activation and effector functions. Each of these
aspects is described in greater detail by Murphy and
colleagues [9]. For instance, ADAM17 processes a number
of cell surface proteins, including TNF, fractalkine and
GM-CSF, all important recruiters and activators of macro-
phages. Ductal lavage of the breast shows the presence of
Available online http://breast-cancer-research.com/content/10/2/205
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Figure 2
Involvement of matrix metalloproteinases (MMPs), a disintegrin and a metalloproteinase (ADAMs), and tissue inhibitor of metalloproteinases
(TIMPs) in immune function. The substrate repertoire generated through shedding, clipping, and regulated-intramembrane processing (RIPping)
provides insight into the role of the metalloproteinase axis in immune cell adhesion and migration, the generation of chemokine gradients, and
humoral and cell-mediated immunity [9]. ICAM, intracellular adhesion molecule; IL, interleukin; TNF, tumor necrosis factor; TNFR, TNF receptor;
VCAM, vascular cell adhesion molecule.macrophages [73] and tumor-associated macrophage
density has been correlated with poor prognosis [74]. CSF1,
an important growth factor for macrophages, is over-
expressed in human breast cancers and its expression
correlates with high grade tumors and poor prognosis [51].
Given these clinical observations, an intriguing avenue for
investigation is the contribution of metalloproteinases to
macrophage function in breast cancer.
Several experimental models have linked TIMP activity to
inflammation, although such a function in breast cancer is
unexplored. TIMP1 deficiency promotes neutrophil accumu-
lation in an inflammatory model of bleomycin-induced lung
injury [75], whereas TIMP2 deficiency has no effect. TIMP3
regulates the bioactivity of the inflammatory cytokine TNF
through its physiological inhibition of the TNF sheddase,
ADAM17/TNF alpha converting enzyme, which is critical for
several physiological systems that depend on TNF [76-79].
Increased numbers of neutrophils are observed in Timp3-/-
remodeling hearts in an otherwise non-inflammatory model of
cardiac pressure overload [77]. Timp3-/- mice are also hyper-
responsive to endotoxin, which causes systemic release of
TNF in a model of innate immunity [78]. Overall, these data
point to select candidates of the metalloproteinase axis that
can potentially participate in inflammation during breast
cancer progression. Specifically, the coordinated action of
TIMP3, ADAM17, and TNF in initiating signal transduction
pathways essential to innate immune responses that can
impact mammary tumourigenesis is currently under investi-
gation in our lab.
In addition to the metalloproteinase-mediated generation of
critical inflammation triggers, metalloproteinases are, in turn,
utilized by immune cells to further propagate the inflammatory
reaction. Of the MMPs, MMP9 is often implicated as an
inflammation-related MMP, with reported roles in
carcinogenesis models [80,81]. In breast cancer samples,
MMP9 in the stroma is found in neutrophils, macrophages,
and T lymphocytes [56]. In a mammary tumorigenesis xeno-
graft model, CD4+ T-cells in the periphery as well as within
the breast tumor expressed high levels of MMP9 [82]. MMP3
is often present in infiltrating T-lymphocytes when found
overexpressed in breast carcinoma [56]. During inflammation,
increased TNF has been shown to induce expression of
collagenases [83]. Notably, the roles of MMPs, such as the
neutrophil collagenase MMP8 primarily produced by inflam-
matory cells [50], and macrophage elastase MMP12 [84],
have yet to be elucidated in mammary tumorigenesis.
The metalloproteinase axis and lymphocytic infiltrate-
positive breast cancer
To address the possible role of MMPs, TIMPs, and ADAMs in
inflammation in breast cancer, we performed expression
profiling of members of these families in the Oncomine
database [85], which contains microarray expression data
from a variety of human cancers. Of the 31 studies on breast
cancer, only the study by van’t Veer and colleagues [86]
recorded lymphocytic infiltration as one of the many clinical
parameters. This study profiled breast tumor mRNA from 117
patients, of which 89 were lymphocytic infiltrate-negative and
28 were lymphocytic infiltrate-positive. Lymphocytic infiltrate
positivity correlated with BRCA mutant and estrogen
Breast Cancer Research    Vol 10 No 2 Hojilla et al.
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Table 1
Metalloproteinase axis mRNA expression in lymphocytic
infiltrate-positive breast cancer
mRNA Differential expression P-value
Timp1 ↓ 0.043
Timp2 NC 0.565
Timp3 ↓ 1.4E-7
Timp4 ↓ 0.004
RECK ↓ 1.2E-6
Mmp1 ↑ 1.4E-5
Mmp2 ↓ 2.8E-4
Mmp3 NC 0.54
Mmp7 ↑ 2.2E-5
Mmp8 NC 0.388
Mmp9 ↑ 0.009
Mmp10 NC 0.47
Mmp11 ↓ 3.3E-4
Mmp12  ↑ 3.5E-7
Mmp13 ↓ 0.02
Mmp14 NC 0.225
Mmp15 NC 0.058
Mmp16 NC 0.416
Mmp17 NC 0.511
Mmp19 ↑ 0.049
Mmp20 ↑ 9.4E-4
Mmp23 ↓ 8.3E-5
Mmp24 NC 0.72
Mmp25 NC 0.794
MmpL1 NC 0.794
Adam8 ↑ 1.8E-4
Adam9 NC 0.574
Adam10 NC 0.25
Adam12 ↓ 0.001
Adam15 NC 0.062
Adam17 ↑ 0.005
Adam19 NC 0.067
Adam23 NC 0.625
Adam28 NC 0.291
Adam33 ↓ 0.029
Adamts1 NC 0.068
Adamts4 NC 0.16
Adamts5 ↓ 0.008
Up and down arrows indicate increased and decreased expression,
respectively; NC indicates no change. ADAM, a disintegrin and a
metalloproteinase; ADAMTS, ADAM with a thrombospondin domain;
MMP, matrix metalloproteinase; RECK, reversion-inducing cysteine-rich
protein with Kazal motifs; TIMP, tissue inhibitor of metalloproteinase.receptor-negative status in an unsupervised two-dimensional
clustering analysis [85]. We found differential expression of
specific MMPs, ADAMs, and TIMPs, when the sample set
was stratified based on lymphocytic infiltration (Table 1). Of
the 22 MMPs examined in their study, several showed
differential expression. Specifically, mRNAs of the inflam-
mation associated MMPs, MMP9 and MMP12, were up-
regulated in lymphocyte infiltrate-positive breast cancers.
ADAM8, a reported sheddase for L-selectin, and ADAM17,
the sheddase for TNF, were also upregulated, consistent with
their suggested pro-inflammatory function. Interestingly, the
mRNA expression of the membrane-type MMPs did not
correlate with lymphocytic infiltrate status in this study, and
ADAMTS expression was also variable. Low expression of
TIMP1, TIMP3, TIMP4, and RECK mRNA significantly
correlated with lymphocytic infiltrate positivity, while TIMP2
was comparable between groups. While this one study
shows intriguing trends, further clinical studies that document
lymphocyte involvement are needed to reveal the association
between global gene expression patterns, inflammation, and
breast cancer.
Conclusion
Although metalloproteinase activity has for some time been
linked to breast cancer as well as mammary gland
development and physiology, it is only recently that the
metalloproteinase axis has been explored in the context of
inflammation and immunity. How the inflammation link
operates in breast cancer is still an open question. It is
apparent that metalloproteinases participate during
morphogenesis and involution, but the current knowledge on
how they may influence immune cells during these critical
windows is completely untested. Similarly, direct evidence for
their role in regulating inflammation/immunity in mammary
tumorigenesis is lacking. On the other hand, data from clinical
breast cancer studies raise intriguing possibilities. By
considering MMP, ADAM and TIMP expression in individual
cell populations, strong associations have emerged with
regard to clinical outcomes in breast cancer patients [68,69].
As discussed above, further analyses of global gene expres-
sion profiles may reveal clinically relevant correlations
between individual metalloproteinase genes and immune cell
involvement in breast cancer. Once the key factors linking
inflammation, metalloproteinase activity, and breast cancer
have been identified, this knowledge will serve to drive novel
therapies and prevention strategies targeting critical
components.
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